家族性肺癌高风险罕见变异:GELCC联盟遗传流行病学发现
该研究对120个高风险肺癌家族进行全基因组和外显子测序,筛选出118个候选罕见有害变异,并在10,085例散发性肺癌和612,970例对照中验证出28个变异。研究识别出GALNT6、MUC4、ERBB3截短变异构成的黏蛋白O-糖基化致病轴,以及DNA修复等通路基因,携带两个及以上变异等位基因者风险呈剂量依赖升高。
要点
- GALNT6、MUC4、ERBB3截短变异构成黏蛋白O-糖基化新致病轴。
- 9个候选变异定位于已知6q23-25连锁区域(ROS1、LAMA2、PRKN、SYNE1)。
- 携带≥2个变异等位基因者家族性肺癌风险呈剂量依赖升高。
核心结论
- 罕见高外显率遗传变异在家族性肺癌易感性中起重要作用,尤其涉及黏蛋白糖基化和DNA修复基因。
研究设计与样本
- 对120个高风险肺癌家族(177例家族性肺癌病例、309名未受累亲属)的胚系DNA进行全基因组和外显子测序。
- 候选变异在10,085例散发性肺癌病例和612,970例对照中进行验证。
主要发现
- 共识别118个候选变异,其中28个在散发性肺癌中获得强统计学支持验证。
- 发现GALNT6、MUC4和ERBB3三个截短变异构成黏蛋白O-糖基化调控的新致病轴。
- 9个顶级命中定位于已知6q23-25连锁区域,包括ROS1、LAMA2、PRKN、SYNE1。
- 其他候选变异聚集于DNA修复(ATM、BRCA2、MLH1)、致癌信号(ERBB3、JAK1、PIM1)和细胞外基质基因(COL6A3、FLG)。
- 基于基因的负荷检验显示RARB、MGMT和EBF1与家族性肺癌易感性强相关。
临床怎么用
- 对高风险家族性肺癌家系可考虑检测GALNT6、MUC4、ERBB3等罕见高外显率变异以辅助风险评估。
- 携带两个及以上变异等位基因者风险呈剂量依赖升高,可能需加强早期筛查。
- 黏蛋白O-糖基化通路和DNA修复基因可作为早期检测和个体化治疗的潜在靶点。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Rare, deleterious germline variants are key contributors to inherited lung cancer (LC) risk. The Genetic Epidemiology of LC Consortium (GELCC) has curated valuable high-risk LC families and is uniquely positioned to uncover rare, high-penetrance variants underlying familial LC (FLC). METHODS: We performed whole-genome and exome sequencing on germline DNA from 120 high-risk LC families (177 FLC cases, 309 unaffected relatives). We prioritized rare (allele frequency <1% in the genome aggregation database), potentially deleterious variants present in two or more FLC cases. These variants were then validated in 10,085 sporadic LC (SLC) cases and 612,970 controls. RESULTS: We identified 118 candidate variants, 28 of which were validated in SLC with strong statistical support. We discovered a novel pathogenic axis of three truncating variants in GALNT6, MUC4, and ERBB3 genes, which are critical regulators of mucin-type O-glycosylation. Nine top hits were mapped to the known 6q23-25 linkage region (ROS1, LAMA2, PRKN, SYNE1). Other candidates were clustered in DNA repair (ATM, BRCA2, MLH1), oncogenic signaling (ERBB3, JAK1, PIM1), and extracellular matrix genes (COL6A3, FLG). Carriers of two or more variant alleles had a strong dose-dependent risk. Furthermore, gene-based burden tests revealed strong associations between RARB, MGMT, and EBF1 with FLC susceptibility. CONCLUSION: Our findings underscore the important role of rare, high-penetrance genetic variants in FLC susceptibility, particularly in mucin glycosylation and DNA repair genes. These findings offer promising targets for early detection and personalized therapies.
引用
- Liu Y, Li Y, Byun J, et al. High-Penetrance Rare Variants Underlying Familial Lung Cancer Risk: Insights From Genetic Epidemiology of Lung Cancer Consortium. J Thorac Oncol. 2025. PMID: 41390056. doi:10.1016/j.jtho.2025.12.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。